The inspection was conducted from 16 December to 20 December 2024, confirmed the facility's strict adherence to Current Good Manufacturing Practices (cGMP).
As a result, ANVISA has granted the facility the Good Manufacturing Practices (GMP) Certificate.
Wanbury is a pharmaceutical company with a presence in the global API market and domestic branded formulations.
The company's consolidated net profit declined 88.12% to Rs 1.22 crore as revenues fell by 8.28% to Rs 133.45 crore in Q3 FY25 as compared with Q3 FY24.
Powered by Capital Market - Live News